Author Interviews, Endocrinology, JAMA, Kidney Disease / 31.01.2017
IV Etelcalcetide (Parsibiv®) Can Treat Elevated PTH in Dialysis Patients More Effectively Than Oral Medication
MedicalResearch.com Interview with:
Geoffrey A. Block, MD
Director of Research at Denver Nephrology
Denver, Colorado
MedicalResearch.com: What is the background for this study?
Response: Secondary hyperparathyroidism is a chronic and progressive disorder characterized by elevations in parathyroid hormone (PTH). It is seen in most patients with advanced chronic kidney disease and has been associated with a number of important adverse health effects such as bone pain, fracture, premature cardiovascular disease, abnormal heart enlargement, pathologic calcium accumulation in blood vessels and tissues and premature death.
Currently there are several classes of drugs used to treat high PTH but each are associated with challenging side effects which limit their effectiveness. Active vitamin D compounds are effective in lowering PTH but do so at the expense of causing elevations in other minerals such as calcium and phosphorus which are felt to be harmful.
An oral drug known as cinacalcet (Sensipar®) is in the class of medicine known as ‘calcimimetics’ and reduces PTH and simultaneously reduces calcium and phosphorus however it must be taken daily due to its short half-life and is commonly associated with nausea when first initiated or the dose is increased. Clinical trials with cinacalcet are suggestive though not conclusive of a beneficial effect on improving cardiovascular events and prolonging life.
(more…)